• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations.

作者信息

Bonovas Stefanos, Peyrin-Biroulet Laurent, Danese Silvio

机构信息

Department of Biomedical Sciences, Humanitas University, Milan, Italy.

IBD Center, Humanitas Clinical and Research Center, Milan, Italy.

出版信息

J Crohns Colitis. 2018 Nov 9;12(10):1257-1258. doi: 10.1093/ecco-jcc/jjy094.

DOI:10.1093/ecco-jcc/jjy094
PMID:29947742
Abstract
摘要

相似文献

1
Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations.炎症性肠病患者使用抗肿瘤坏死因子与淋巴瘤风险关联的Meta分析：方法学考量
J Crohns Colitis. 2018 Nov 9;12(10):1257-1258. doi: 10.1093/ecco-jcc/jjy094.
2
Comment on 'Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations'.关于“抗肿瘤坏死因子的使用与炎症性肠病患者淋巴瘤风险之间关联的荟萃分析：方法学考量”的评论
J Crohns Colitis. 2018 Nov 9;12(10):1259. doi: 10.1093/ecco-jcc/jjy096.
3
Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis.抗肿瘤坏死因子 α 制剂治疗炎症性肠病患者的淋巴瘤风险：系统评价和荟萃分析。
J Crohns Colitis. 2018 Aug 29;12(9):1042-1052. doi: 10.1093/ecco-jcc/jjy065.
4
Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?在 IBD 患者中，使用抗 TNF 治疗是否会增加淋巴瘤和恶性肿瘤的风险？
Curr Drug Targets. 2010 Feb;11(2):179-86. doi: 10.2174/138945010790309867.
5
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.抗肿瘤坏死因子α制剂诱导治疗炎症性肠病后粪便钙卫蛋白检测：一年时临床反应和黏膜愈合的预测
Dig Liver Dis. 2014 Nov;46(11):974-9. doi: 10.1016/j.dld.2014.07.013. Epub 2014 Aug 2.
6
Evaluation of de-escalation of anti-TNF-α therapy in inflammatory bowel disease.炎症性肠病中抗TNF-α治疗方案降级的评估
Gastroenterol Hepatol. 2019 Feb;42(2):133-140. doi: 10.1016/j.gastrohep.2018.10.010. Epub 2018 Dec 27.
7
Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?炎症性肠病中的淋巴瘤风险：是疾病本身还是其治疗导致的？
Inflamm Bowel Dis. 2007 Oct;13(10):1299-307. doi: 10.1002/ibd.20211.
8
Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment.综述文章：炎症性肠病及免疫抑制治疗相关的淋巴瘤风险
Aliment Pharmacol Ther. 2001 Aug;15(8):1101-8. doi: 10.1046/j.1365-2036.2001.01023.x.
9
Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in chronic inflammatory bowel disease.慢性炎症性肠病中肿瘤坏死因子及其抑制剂的循环和黏膜浓度
Dan Med Bull. 1993 Apr;40(2):247-9.
10
Tumour necrosis factor and inflammatory bowel disease.肿瘤坏死因子与炎症性肠病
Br J Surg. 1997 Aug;84(8):1051-8.